Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa/IIb study of BL-B01D1 in advanced or metastatic urothelial and other solid tumors
CTR20230720Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- May 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab brengitecan in transitional cell carcinoma (TCC), prostate cancer (PCa), Nonhematologic neoplasms, sponsored by Biokin Pharmaceutical. Started May 2023; status: active.
02
Drugs
izalontamab brengitecan
03
Conditions
transitional cell carcinoma (TCC)prostate cancer (PCa)Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20230720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230720.